Menu Search
Equities

Fibrobiologics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
SG0:FRA

Fibrobiologics Inc

Actions
  • Price (EUR)0.172
  • Today's Change-0.044 / -20.37%
  • Shares traded4.00k
  • 1 Year change-89.11%
  • Beta--
Data delayed at least 15 minutes, as of Feb 06 2026 07:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

FibroBiologics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). It is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. It is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.

  • Revenue in USD (TTM)0.00
  • Net income in USD-18.50m
  • Incorporated2021
  • Employees13.00
  • Location
    Fibrobiologics Inc455 E. Medical Center Blvd, Suite 300HOUSTON 77598United StatesUSA
  • Phone+1 (281) 671-5150
  • Fax+1 (302) 655-5049
  • Websitehttps://fibrobiologics.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.